Ferroptosis inhibition enhances liver and lung graft function

Ischemia-reperfusion injury (IRI) is a major clinical challenge in transplantation, vascular surgeries, myocardial infarction, and stroke. Disruption of energy and redox homeostasis triggers ferroptosis, a regulated, iron-dependent form of cell death, leading to organ dysfunction. We identify an early and transient increase of lipid peroxidation in human liver transplants and validate it as a therapeutic target. FXT-001, a ferroptosis inhibitor with dual radical and iron-trapping activity, provides robust protection in preclinical models, including ex situ perfusion of porcine liver and lung grafts. In a split ex vivo machine perfusion setting using declined human donors, FXT-001 treatment preserves graft viability, whereas untreated lungs deteriorate. We also develop FXT-002 and FXT-003 with enhanced pharmacokinetic and safety profiles. These findings support the use of ferroptosis inhibitors as a therapeutic strategy in transplantation and other IRI-associated conditions.

Authors

Institutions

Publication Details

Journal
Cell
Published
2026-05-01
DOI
https://doi.org/10.1016/j.cell.2026.04.024
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ferroptosis inhibition enhances liver and lung graft function

Koen Augustyns, Christine Gaillet, Greta Klejborowska, Dieter Van Beersel et al.
Cell
Ferroptosis and cancer prognosis
article

Ferroptosis inhibition enhances liver and lung graft function

Koen Augustyns, Christine Gaillet, Greta Klejborowska, Dieter Van Beersel, Joris Blondeel, Behrouz Hassannia, Camilla Scarpellini, Jan‐Michael Abicht, Caroline Lanthier, Nicholas Gilbo, J. Pirenne, Ina Jochmans, Ludovic Colombeau, Laurens J. Ceulemans, Michele Wölk, B Reichart, Geraldine Veeckmans, Lene Devos, Magali Walravens, H. Winter, Sebastian Müller, Matthias Längin, Martin Bender, Arne Neyrinck, Diethard Monbaliu, Maria Fedorova, Raphaël Rodriguez, Tom Vanden Berghe
article en

Abstract

Ischemia-reperfusion injury (IRI) is a major clinical challenge in transplantation, vascular surgeries, myocardial infarction, and stroke. Disruption of energy and redox homeostasis triggers ferroptosis, a regulated, iron-dependent form of cell death, leading to organ dysfunction. We identify an early and transient increase of lipid peroxidation in human liver transplants and validate it as a therapeutic target. FXT-001, a ferroptosis inhibitor with dual radical and iron-trapping activity, provides robust protection in preclinical models, including ex situ perfusion of porcine liver and lung grafts. In a split ex vivo machine perfusion setting using declined human donors, FXT-001 treatment preserves graft viability, whereas untreated lungs deteriorate. We also develop FXT-002 and FXT-003 with enhanced pharmacokinetic and safety profiles. These findings support the use of ferroptosis inhibitors as a therapeutic strategy in transplantation and other IRI-associated conditions.

Cell
Centre National de la Recherche Scientifique (FR), University of Antwerp (BE), Inserm (FR), University of Liège (BE), Université Paris Sciences et Lettres (FR), LMU Klinikum (DE), University Hospital Carl Gustav Carus (DE), Technische Universität Dresden (DE), Ludwig-Maximilians-Universität München (DE), KU Leuven (BE)
Fonds Wetenschappelijk Onderzoek, Stichting Tegen Kanker, Universiteit Antwerpen
Openalex Percentile: Top 7%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.